Sanofi says tolebrutinib drug delayed progressive MS by 31%
FRANKFURT (Reuters) – Sanofi (NASDAQ:SNY) said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the…
Input your search keywords and press Enter.